November 4, 2015
The Pharmaceuticals and Medical Devices Agency (PMDA) said on October 30 that Ono Pharmaceutical’s anti-PD-1 antibody nivolumab (brand name: Opdivo) is now under review for the possible risk of type 1 diabetes. The Ministry of Health, Labor and Welfare is...read more